You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 17, 2025

CLINICAL TRIALS PROFILE FOR TRILIPIX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TRILIPIX

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00639158 ↗ Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood Completed Abbott Phase 3 2008-02-01 The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood.
NCT00300430 ↗ Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Completed Abbott Phase 3 2006-09-01 The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.
NCT00813527 ↗ Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels Completed Takeda Phase 2 2006-02-01 The purpose of this study is to compare changes in cholesterol levels in patients with elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and fenofibrate.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 3 of 3 entries

Clinical Trial Conditions for TRILIPIX

Condition Name

2220-0.200.20.40.60.811.21.41.61.822.2DyslipidemiaHealthyMixed Dyslipidemia[disabled in preview]
Condition Name for TRILIPIX
Intervention Trials
Dyslipidemia 2
Healthy 2
Mixed Dyslipidemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

333000.511.522.53Coronary Artery DiseaseMyocardial IschemiaDyslipidemias[disabled in preview]
Condition MeSH for TRILIPIX
Intervention Trials
Coronary Artery Disease 3
Myocardial Ischemia 3
Dyslipidemias 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TRILIPIX

Trials by Country

+
Trials by Country for TRILIPIX
Location Trials
United States 61
Canada 2
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for TRILIPIX
Location Trials
Illinois 4
South Carolina 3
Georgia 3
California 3
Tennessee 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TRILIPIX

Clinical Trial Phase

28.6%42.9%28.6%000.511.522.53Phase 4Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for TRILIPIX
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

77.8%22.2%001234567CompletedTerminated[disabled in preview]
Clinical Trial Status for TRILIPIX
Clinical Trial Phase Trials
Completed 7
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TRILIPIX

Sponsor Name

trials011223344AbbottTakedaUniversity of Utah[disabled in preview]
Sponsor Name for TRILIPIX
Sponsor Trials
Abbott 4
Takeda 1
University of Utah 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

54.5%36.4%9.1%00123456IndustryOtherNIH[disabled in preview]
Sponsor Type for TRILIPIX
Sponsor Trials
Industry 6
Other 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

TRILIPIX (Fenofibric Acid): Clinical Trials, Market Analysis, and Projections

Introduction to TRILIPIX

TRILIPIX, also known as fenofibric acid, is a prescription medication used to treat cholesterol and triglyceride levels in the blood. It is designed to lower low-density lipoprotein (LDL) cholesterol, increase high-density lipoprotein (HDL) cholesterol, and reduce very high levels of triglycerides, thereby helping to reduce the risk of pancreatitis and cardiovascular events[1].

Clinical Trials Update

ACCORD Lipid Trial

One of the significant clinical trials involving TRILIPIX is the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid trial. This trial evaluated the efficacy and safety of fenofibrate plus simvastatin combination therapy versus simvastatin alone in patients with type 2 diabetes mellitus. The results showed no significant difference in the risk of major adverse cardiac events between the two treatment groups. However, a subgroup analysis indicated an increased risk for major adverse cardiac events in women receiving the combination therapy compared to simvastatin alone, although the clinical significance of this finding is unclear[1].

Combination Therapy with Statins

TRILIPIX has been studied in combination with various statins, including rosuvastatin, atorvastatin, and simvastatin. A Phase III study presented at the American College of Cardiology’s 2009 Scientific Sessions demonstrated that TRILIPIX combined with rosuvastatin calcium improved LDL cholesterol, HDL cholesterol, and triglycerides compared to rosuvastatin alone or TRILIPIX alone. This combination therapy showed greater improvements in all three key lipids than monotherapy with either drug[4].

Ongoing and Required Trials

Based on the results from the ACCORD Lipid trial and other clinical trials, the FDA has required the manufacturer of TRILIPIX to conduct a randomized, double-blind, placebo-controlled clinical trial. This trial aims to evaluate the cardiovascular effects of TRILIPIX in combination with a statin versus statin alone in patients at high risk for cardiovascular disease who are already at their LDL cholesterol goal on statin therapy but have residually high triglycerides and low HDL cholesterol[1].

Market Analysis

Current Market Position

TRILIPIX is part of the broader dyslipidemia drugs market, which includes a variety of lipid-lowering therapies. The global dyslipidemia market is significant, with sales estimated to reach $29.2 billion by 2025, growing at a CAGR of 10.1% from 2015 to 2025. The US is the largest market, contributing approximately 61.5% of total sales[5].

Co-Promotion and Market Reach

To enhance the market reach of TRILIPIX, Abbott Laboratories and AstraZeneca have entered into a co-promotion agreement. This partnership aims to increase the share of voice for TRILIPIX and reach out to more physicians, particularly those with whom AstraZeneca has established relationships[2].

Competitive Landscape

The dyslipidemia market is highly competitive, with various classes of drugs including statins, fibrates (like TRILIPIX), ezetimibe, and newer biologics targeting PCSK9. The market is expected to be driven by the uptake of these revolutionary biologics, which are forecasted to reach peak sales of $9.5 billion by 2025. However, cost-effective therapies like TRILIPIX will remain crucial due to pricing being a significant barrier to uptake[5].

Market Projections

Growth Drivers

The dyslipidemia market is expected to grow strongly, driven by several factors:

  • Increasing Prevalence of Dyslipidemia: The rising incidence of dyslipidemia, particularly in the context of growing obesity and diabetes rates, will drive the demand for lipid-lowering therapies.
  • Advancements in Treatment Options: The introduction of new and more effective treatments, such as PCSK9 inhibitors, will contribute to market growth.
  • Combination Therapies: The efficacy of combination therapies, such as TRILIPIX with statins, will continue to support market expansion[5].

Challenges and Opportunities

Despite the positive growth outlook, the market faces several challenges:

  • Pricing and Reimbursement: High drug prices and reimbursement issues can limit the adoption of newer therapies.
  • Unmet Needs: There remains a high level of unmet needs in the dyslipidemia market, particularly for patients who do not achieve adequate lipid control with current therapies. Pipeline drugs targeting these needs could provide significant opportunities for growth[5].

Key Takeaways

  • TRILIPIX is a fenofibric acid drug used to treat cholesterol and triglyceride levels.
  • Clinical Trials: The ACCORD Lipid trial and other studies have shown mixed results regarding the cardiovascular benefits of TRILIPIX, leading to further required trials.
  • Market Position: TRILIPIX is part of a growing dyslipidemia market, with a strong co-promotion agreement to enhance its reach.
  • Growth Drivers: The market is driven by increasing prevalence of dyslipidemia, advancements in treatment options, and the efficacy of combination therapies.
  • Challenges: Pricing and reimbursement issues, along with unmet needs, pose challenges and opportunities for growth.

FAQs

What is TRILIPIX used for?

TRILIPIX (fenofibric acid) is used to treat cholesterol and triglyceride levels in the blood by lowering LDL cholesterol, increasing HDL cholesterol, and reducing high levels of triglycerides.

What were the findings of the ACCORD Lipid trial?

The ACCORD Lipid trial found no significant difference in major adverse cardiac events between patients treated with fenofibrate plus simvastatin and those treated with simvastatin alone. However, a subgroup analysis suggested an increased risk for major adverse cardiac events in women receiving the combination therapy.

How does TRILIPIX perform in combination with statins?

Studies have shown that TRILIPIX in combination with statins like rosuvastatin improves LDL cholesterol, HDL cholesterol, and triglycerides more effectively than either drug alone.

What is the current market outlook for dyslipidemia drugs?

The global dyslipidemia market is expected to grow at a CAGR of 10.1% from 2015 to 2025, reaching $29.2 billion by 2025, driven by new treatment options and increasing prevalence of dyslipidemia.

What are the main challenges facing the dyslipidemia market?

The main challenges include high drug prices, reimbursement issues, and the need for therapies that address the unmet needs of patients who do not achieve adequate lipid control with current treatments.

Sources

  1. FDA Drug Safety Communication: Review Update of Trilipix (fenofibric acid) and the ACCORD Lipid trial - FDA
  2. Abbott, AZ extend co-promotion to Trilipix - MM+M
  3. Dyslipidemia Drugs Market and Forecast 2024-2031 - iHealthcareAnalyst
  4. New Data for Abbott Laboratories's TRILIPIX(R) (fenofibric acid) in combination with rosuvastatin calcium - Biospace
  5. Dyslipidemia – Global Drug Forecast and Market Analysis to 2025 - GlobalData

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.